Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR18247-101] to IL-27-A
- Suitable for: WB, IP
- Reacts with: Mouse
Product nameAnti-IL-27-A antibody [EPR18247-101]
See all IL-27-A primary antibodies
DescriptionRabbit monoclonal [EPR18247-101] to IL-27-A
Tested applicationsSuitable for: WB, IPmore details
Unsuitable for: Flow Cyt,ICC/IF or IHC-P
Species reactivityReacts with: Mouse
Recombinant fragment within Mouse IL-27-A aa 1 to the C-terminus. The exact sequence is proprietary.
Database link: Q8K3I6
- WB: RAW 264.7 (treated with 100ng/ml LPS for 6h) whole cell lysate. IP: RAW 264.7 (treated with 1µg/ml LPS for 6h) whole cell lysate.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol, 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab190831 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 27 kDa (predicted molecular weight: 27 kDa).|
FunctionCytokine with pro- and anti-inflammatory properties, that can regulate T helper cell development, suppress T-cell proliferation, stimulate cytotoxic T cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL-27 subunit p28 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of proinflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replivation.
Tissue specificityExpressed in monocytes and in placenta.
Sequence similaritiesBelongs to the IL-6 superfamily.
Cellular localizationSecreted. Does not seem to be secreted without coexpression of EBI3.
- Information by UniProt
- EBI3 antibody
- IL 27 antibody
- IL 27 p28 subunit antibody
All lanes : Anti-IL-27-A antibody [EPR18247-101] (ab190831) at 1/1000 dilution
Lane 1 : Untreated RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate
Lane 2 : RAW 264.7 (treated with 100ng/ml LPS for 6h) whole cell lysate
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 27 kDa
Observed band size: 27 kDa
Exposure time: 3 minutes
Blocking and dilution buffer: 5% NFDM/TBST.
The expression profile/ molecular weight observed is consistent with what has been described in the literature (PMID: 19620301, PMID: 12121660).
This blot was developed using a higher sensitivity ECL substrate.
IL-27-A was immunoprecipitated from 0.35 mg of RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) (treated with 1μg/ml LPS for 6h) whole cell lysate with ab190831 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab190831 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution.
Lane 1: RAW 264.7 (treated with 1μg/ml LPS for 6h ) whole cell lysate 10 μg (Input).
Lane 2: ab190831 IP in RAW 264.7 (treated with 1μg/ml LPS for 6h) whole cell lysate.
Lane 3: : Rabbit monoclonal IgG (ab172730) instead of ab190831 in RAW 264.7 (treated with 1μg/ml LPS for 6h) whole cell lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 1 second.
The molecular weight observed is consistent with what has been described in the literature (PMID: 19620301, PMID: 12121660).
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab190831 has not yet been referenced specifically in any publications.